Related Experiment Videos
Weekly low-dose methotrexate therapy for cutaneous sarcoidosis
G F Webster1, L K Razsi, M Sanchez
1Department of Dermatology, Thomas Jefferson Medical College, Philadelphia, PA 19107.
Journal of the American Academy of Dermatology
|March 1, 1991
Summary
Low-dose oral methotrexate effectively treated severe, treatment-resistant cutaneous sarcoidosis in three patients. Facial lesions showed the best response, with maximal effects observed after 6 to 9 months of weekly treatment.
Area of Science:
- Dermatology
- Rheumatology
- Immunology
Background:
- Cutaneous sarcoidosis is a multisystem granulomatous disease.
- Severe, treatment-resistant cases pose significant therapeutic challenges.
- Limited effective treatment options exist for refractory cutaneous sarcoidosis.
Observation:
- Three patients with severe, treatment-resistant cutaneous sarcoidosis were evaluated.
- Treatment involved low-dose oral methotrexate administered weekly.
- Clinical observations focused on the response of various cutaneous lesions.
Findings:
- Significant improvement was observed in facial granulomas and ulcerations.
- A noticeable response to methotrexate became apparent within weeks.
- Maximal therapeutic effect required a treatment duration of 6 to 9 months.
Implications:
- Low-dose oral methotrexate is a viable treatment option for severe, refractory cutaneous sarcoidosis.
- Methotrexate demonstrates efficacy in improving facial sarcoidosis lesions.
- Extended treatment duration is necessary to achieve optimal outcomes with methotrexate therapy.